BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) today announced that it has signed a collaboration agreement with JHL Biotech for the development and commercialization of BL-9020, a novel monoclonal antibody for the treatment of Type 1 diabetes.

JHL Biotech is a biotech company that develops, produces and commercializes biological drugs. According to the collaboration agreement, JHL Biotech will be responsible for all process development and manufacturing of BL-9020 during its pre-clinical and clinical development stages, and BioLineRx will be responsible for all pre-clinical development of BL-9020. Responsibility for clinical development of BL-9020 will be shared by the parties on a regional basis.

JHL Biotech will have global manufacturing rights to BL-9020, along with development and commercialization rights in China and Southeast Asia, and BioLineRx will have development and commercialization rights in the rest of the world. In all development and manufacturing of BL-9020, JHL Biotech will adhere to US Food and Drug Administration (FDA) guidelines and regulations. Each party will also be entitled to single-digit royalties on the sale of BL-9020 in the other party's respective territory.

Published by Globes [online], Israel business news - www.globes-online.com - on January 8, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014